...
首页> 外文期刊>Neurology: Official Journal of the American Academy of Neurology >SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage.
【24h】

SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage.

机译:SSRI和他汀类药物使用增加的风险蛛网膜下腔出血后血管痉挛。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Use of medications with vasoconstrictive or vasodilatory effects can potentially affect the risk for vasospasm after aneurysmal subarachnoid hemorrhage (SAH). METHODS: Using International Classification of Diseases-9 diagnostic codes followed by medical record review, the authors identified 514 patients with SAH admitted between 1995 and 2003 who were evaluated for vasospasm between days 4 and 14. The authors determined risks for vasospasm, symptomatic vasospasm, and poor clinical outcomes in patients with documented pre-hemorrhagic use of calcium channel blockers, beta-receptor blockers, ACE inhibitors, aspirin, selective serotonin reuptake inhibitors (SSRIs), non-SSRI vasoactive antidepressants, or statins. RESULTS: Vasospasm developed in 62%, and symptomatic vasospasm in 29% of the cohort. On univariate analysis, the risk for all vasospasm tended to increase in patients taking SSRIs (p = 0.09) and statins (p = 0.05); SSRI use increased the risk for symptomatic vasospasm (p = 0.028). The Cochran-Armitage trend test showed that the proportion of patients taking SSRIs and statins increased significantly across three worsening categories (none, asymptomatic, symptomatic) of vasospasm. Logistic regression analysis showed that SSRI use tended to predict all vasospasm (O.R. 2.01 [0.91 to 4.45]), and predicted symptomatic vasospasm (O.R. 1.42 [1.06 to 4.33]). Statin exposure increased the risk for vasospasm (O.R. 2.75 [1.16 to 6.50]), perhaps from abrupt statin withdrawal (O.R. 2.54 [0.78 to 8.28]). Age < 50 years, Hunt-Hess grade 4 or 5, and Fisher Group 3 independently predicted all vasospasm, symptomatic vasospasm, poor discharge clinical status, and death. CONCLUSION: Selective serotonin reuptake inhibitor and statin users have a higher risk for subarachnoid hemorrhage-related vasospasm. Whether the underlying disease indication, direct actions, or rebound effects from abrupt drug withdrawal account for the associated risk warrants further investigation.
机译:背景:药物的使用vasoconstrictive或血管扩张性效果可能影响血管痉挛后的风险动脉瘤性蛛网膜下腔出血(SAH)。方法:使用国际分类其次是医疗Diseases-9诊断代码记录审查,作者确定了514SAH患者承认在1995年和2003年之间评估血管痉挛之间天4是谁和14。血管痉挛、症状性血管痉挛和贫穷记录患者的临床结果pre-hemorrhagic使用钙通道阻滞剂,β受体阻滞剂、血管紧张素转换酶抑制剂阿司匹林,选择性5 -羟色胺再摄取抑制剂(SSRIs),非ssri抗抑郁药物作用于血管的,或他汀类药物。结果:血管痉挛了62%,症状性血管痉挛在人群的29%。单变量分析,所有的血管痉挛的风险倾向于增加病人服用ssri类药物(p =0.09)和他汀类药物(p = 0.05);症状性血管痉挛的风险(p = 0.028)。测试表明,该Cochran-Armitage趋势比例的病人服用SSRIs和他汀类药物在三个恶化显著增加类别(无,无症状,有症状)血管痉挛。SSRI使用倾向于预测血管痉挛(业主2.01[0.91 - 4.45]),并预测症状性血管痉挛(业主1.42[1.06 - 4.33])。他汀类药物暴露血管痉挛的风险增加(业主2.75[1.16 - 6.50]),也许突然他汀类药物戒断(业主2.54[0.78 - 8.28])。< 50年,Hunt-Hess年级4或5,费舍尔组3个独立预测血管痉挛,症状性血管痉挛,可怜的放电临床状态,和死亡。5 -羟色胺再摄取抑制剂和他汀类用户对蛛网膜下腔有更高的风险吗hemorrhage-related血管痉挛。潜在疾病迹象,直接行动,或从突然停药反弹效果考虑相关风险进一步认股权证调查。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号